Renal complications resulting from type 2 diabetes mellitus are costly and common. Finding optimal therapy is important for the prevention and management of diabetic nephropathy. Research has focused on antihypertensive agents that modify the renin-angiotensin-aldosterone system. Because of their effects on the glomerulus, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) have been studied as interventions at various stages of diabetic nephropathy. The ACE inhibitors may delay the progression to microalbuminuria and then clinical albuminuria. The ARBs decrease albuminuria in patients with microalbuminuria and decrease adverse renal events, specifically the progression to end-stage renal disease in patients with clinical albuminuria and hypertension. Limited data suggest that combination therapy with ACE inhibitors and ARBs may slow the progression of microalbuminuria to clinical albuminuria. Because of the variability in degree of albuminuria evaluated and in study designs (numbers of patients, study duration, drug dosages, and outcomes measured), a detailed review of the available literature about ACE inhibitors and ARBs in the prevention or treatment of diabetic nephropathy may provide insight to clinicians.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1592/phco.2005.25.11.1602 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Manifestations.
Alzheimers Dement
December 2024
University of Nebraska Medical Center, Omaha, NE, USA.
Background: This pilot study addresses unmet needs for empirical evidence on real-world data (RWD) on sleep to inform pharmacological management in older adults at-risk for neurodegenerative conditions. Polypharmacy is prevalent among older adults, with potential adverse effects on physiological functions, including sleep. Sleep disturbances are prevalent in aging, may signal onset of Alzheimer's disease (AD), potentially contributing to the underlying pathology.
View Article and Find Full Text PDFBackground: Seizures, traumatic brain injury (TBI), and dementia increase in prevalence with age. However, the role of seizure and TBI on cognitive impairment risk (CI) is unclear. This study investigated how a diagnosis of seizures and TBI was associated with the progression to CI and assessed the role of medications.
View Article and Find Full Text PDFConstruction of Clinical Predictive Models for Heart Failure Detection Using Six Different Machine Learning Algorithms: Identification of Key Clinical Prognostic Features.
Int J Gen Med
December 2024
Department of Cardiology, Shaanxi Provincial People's Hospital, Xi'an, People's Republic of China.
Purpose: Heart failure (HF) is a clinical syndrome in which structural or functional abnormalities of the heart result in impaired ventricular filling or ejection capacity. In order to improve the adaptability of models to different patient populations and data situations. This study aims to develop predictive models for HF risk using six machine learning algorithms, providing valuable insights into the early assessment and recognition of HF by clinical features.
View Article and Find Full Text PDFEstimating optimal thresholds for adherence to RASA medications among older adults with hypertension.
J Manag Care Spec Pharm
January 2025
University of Mississippi School of Pharmacy, University.
Background: The Centers for Medicare and Medicaid Services (CMS) Star Ratings program incentivizes health plans in Medicare to improve performance on a variety of quality measures such as adherence to renin-angiotensin system antagonists (RASAs). Adherence to RASA medications, defined as having a proportion of days covered (PDC) of at least 80%, has been improving for several years, suggesting that further investigation is needed to assess the appropriateness of the current 80% PDC threshold for medication adherence as an indicator of quality. The 80% PDC threshold has been found to be associated with improved health care resource utilization outcomes; however, little evidence exists to show that this threshold is optimal.
View Article and Find Full Text PDFNon-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients.
Front Pharmacol
December 2024
School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
Introduction: The benefit of secondary prevention in hypertensive patients with peripheral arterial disease (PAD) is based on continual simultaneous taking of statins, antiplatelet agents and antihypertensive agents, preferably angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Our study was aimed at a) the analysis of the extent of non-persistence with multiple medication classes, and b) identifying factors associated with the likelihood of non-persistence.
Methods: In our cohort study, 3,401 hypertensive patients (1,853 females and 1,548 males) aged ≥65 years treated simultaneously with statins, antiplatelet agents and ACEIs/ARBs and in whom PAD was newly diagnosed during 2012 were analysed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!